iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/34756204/
Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Nov 13;398(10313):1799-1800.
doi: 10.1016/S0140-6736(21)02316-3. Epub 2021 Oct 28.

Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland

Zoe Grange  1 , Audrey Buelo  1 , Christopher Sullivan  1 , Emily Moore  1 , Utkarsh Agrawal  2 , Khaled Boukhari  1 , Iain McLaughlan  1 , Diane Stockton  1 , Colin McCowan  2 , Chris Robertson  3 , Aziz Sheikh  4 , Josephine L K Murray  1
Affiliations
Comment

Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland

Zoe Grange et al. Lancet. .

Erratum in

  • Department of Error.
    [No authors listed] [No authors listed] Lancet. 2021 Nov 13;398(10313):1802. doi: 10.1016/S0140-6736(21)02431-4. Epub 2021 Nov 8. Lancet. 2021. PMID: 34762856 Free PMC article. No abstract available.
No abstract available

PubMed Disclaimer

Conflict of interest statement

ZG, AB, and CS contributed equally. AS and JLKM contributed equally. AS and CR are members of the Scottish Government Chief Medical Officer's COVID-19 Advisory Group. AS is a member of the NERVTAG Risk Stratification Subgroup and an unfunded member of AstraZeneca's COVID-19 strategic consultancy group, the Thrombocytopenia Taskforce. CM reports research funding from the Medical Research Council, Health Data Research UK, National Institute for Health Research, and the Scottish Chief Science Office. CR is a member of the Scientific Pandemic Influenza Group on Modelling and the Medicines and Healthcare products Regulatory Agency COVID-19 Vaccine Benefit and Risk Working Group. JLKM is a member of the COVID Scottish National Incident Management Team. All other authors report no competing interests. EAVE II is funded by the Medical Research Council with the support of BREATHE, the health data research hub for respiratory health, which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. Additional support was provided through Public Health Scotland and the Scottish Government Director-General Health and Social Care. The research for this Correspondence is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation. We thank Dave Kelly from Albasoft for support with making primary care data available and James Pickett, Wendy Inglis-Humphrey, Vicky Hammersley, Maria Georgiou, Laura Gonzalez Rienda, Pam McVeigh, Amanda Burridge, Sumedha Asnani-Chetal, and Afshin Dastafshan for project management and administration support. We acknowledge the support of the EAVE II Patient Advisory Group. UA and CM acknowledge funding from Health Data Research UK (Measuring and Understanding Multimorbidity using Routine Data in the UK – HDR-9006; CFC0110). The funding source had no involvement in data collection, study design, data analysis, interpretation of findings, or the decision to publish.

Comment in

Comment on

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397:1819–1829. - PMC - PubMed
    1. Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021;397:1646–1657. - PMC - PubMed
    1. Centers for Disease Control and Prevention Interim clinical considerations for use of COVID-19 vaccines. Aug 31, 2021. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-v...
    1. Albitar O, Ballouze R, Ooi JP, Ghadzi SMS. Risk factors for mortality among COVID-19 patients. Diabetes Res Clin Pract. 2020;166 - PMC - PubMed
    1. Agrawal U, Katikireddi SV, McCowan C, et al. COVID-19 hospital admissions and deaths post BNT162b2 and ChAdOx1 vaccinations: national prospective cohort study of 2·57 million people in Scotland. Lancet Respir Med. 2021 doi: 10.1016/S2213-2600(21)00380-5. published online Sept 29. - DOI - PMC - PubMed